Diamyd Medical

Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products. The first, called Diamyd, is an injection of recombinant human GAD65 protein combined with alum, meant to induce immune tolerance in those at high risk of developing type 1 diabetes. The second, Remygen, is a controlled-release form of GABA, intended to stimulate beta cell growth and reverse diabetes.[1] Diamyd is the subject of a Phase III clinical trial; Remygen is the subject of a combined Phase I/II clinical trial.[2]

The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå.[3]

References
  1. "Products in Clinical Development". Diamyd Medical AB. Retrieved 20 February 2023.
  2. "Clinical Trials". Diamyd Medical AB. Retrieved 20 February 2023.
  3. "Annual Report 2021/2022" (PDF). Diamyd Medical AB. Retrieved 20 February 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.